A Tale of Two Drugs: Meridia and Avandia, and the Issues that Separated Them
This article was originally published in RPM Report
Executive Summary
Avandia and Meridia are different drugs with parallel regulatory histories: both are long-marketed treatments for metabolic disease. Both have an increased risk of cardiovascular events. And both were considered for withdrawal at roughly the same time by the same FDA division. But while there were many similarities between the two, the reviews were markedly different with markedly different outcomes.
You may also be interested in...
The Inevitable Outcome: Diabetes Safety Model Expands To Weight Loss…And Beyond?
The cardiovascular outcomes standard used for diabetes drugs since 2008 is moving to weight loss. That is important in itself, but also for what it says about the lessons FDA has taken from the diabetes experience – and what it might mean about regulatory expectations for other chronic drug classes in the future.
The Inevitable Outcome: Diabetes Safety Model Expands to Weight Loss…and Beyond?
The cardiovascular outcomes standard used for diabetes drugs since 2008 is moving to weight loss. That is important in itself, but also for what it says about the lessons FDA has taken from the diabetes experience—and what it might mean about regulatory expectations for other chronic drug classes in the future.
Setting the Stage: Qnexa and the Power of REMS
Vivus’ second trip to an advisory panel was a much happier one, with the company’s weight loss therapy garnering an overwhelming “yes” vote on approvability. The key change? A Risk Evaluation & Mitigation Strategy that will be precedent setting if approved—and that demonstrates the power of REMS even if FDA moves in a different direction with this application.